Pulmonx (NASDAQ:LUNG) Releases Earnings Results, Beats Estimates By $0.04 EPS

Pulmonx (NASDAQ:LUNG) released its quarterly earnings results on Wednesday. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04, FiscalAI reports. Pulmonx had a negative return on equity of 92.94% and a negative net margin of 60.09%.The business had revenue of $22.76 million during the quarter, compared to analysts’ expectations of $22.39 million.

Here are the key takeaways from Pulmonx’s conference call:

• Second-quarter revenue was $22.8 million, down 5% year over year. U.S. revenue declined 4% but increased 7% sequentially, while the international decline was attributed to the suspension of China shipments; 12 new U.S. treating centers were added.
• Management reiterated its 2026 revenue guidance of $90 million to $92 million and expects to return to year-over-year growth later this year, potentially exiting 2026 at or near double-digit growth as new sales representatives ramp.
• Cost reductions produced meaningful operating leverage: net loss fell 34% to $10.1 million and adjusted EBITDA loss improved nearly 40% to $5.1 million. Full-year operating expenses are now expected at $109 million to $111 million, with cash burn projected at approximately $23 million.
• Pulmonx renewed its Chinese registration certificate in June and expects to resume distributor shipments in early 2027; excluding China, international revenue grew 9% on a constant-currency basis. Second-quarter gross margin rose to 78%, and full-year guidance was raised to approximately 76%.
• Enrollment in the pivotal CONVERT II trial for AeriSeal is progressing toward completion in 2027. Management views AeriSeal as a potential tool to expand the global addressable market for Zephyr valves by roughly 20%, with earlier commercial availability possible in certain European markets after local enrollment is complete.

Pulmonx Stock Up 35.6%

Shares of LUNG stock traded up $0.45 during trading on Thursday, reaching $1.70. The company’s stock had a trading volume of 2,759,701 shares, compared to its average volume of 468,979. Pulmonx has a 1-year low of $1.13 and a 1-year high of $2.89. The stock’s 50-day moving average price is $1.41 and its 200 day moving average price is $1.47. The company has a market capitalization of $71.60 million, a price-to-earnings ratio of -1.30 and a beta of 0.30. The company has a debt-to-equity ratio of 0.81, a current ratio of 4.91 and a quick ratio of 4.04.

Institutional Trading of Pulmonx

Several hedge funds have recently modified their holdings of LUNG. ExodusPoint Capital Management LP acquired a new position in Pulmonx during the 4th quarter worth $4,312,000. Vestal Point Capital LP acquired a new stake in Pulmonx in the 3rd quarter valued at about $1,345,000. Bank of America Corp DE raised its position in Pulmonx by 556.6% in the 2nd quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock valued at $1,246,000 after purchasing an additional 407,971 shares in the last quarter. Birchview Capital LP purchased a new position in shares of Pulmonx in the 4th quarter valued at about $554,000. Finally, Kotler Kevin purchased a new position in shares of Pulmonx in the 4th quarter valued at about $442,000. 91.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on LUNG shares. D. Boral Capital reiterated a “buy” rating and set a $14.00 price target on shares of Pulmonx in a research report on Thursday, April 30th. Wall Street Zen upgraded shares of Pulmonx from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pulmonx in a research report on Monday, July 13th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.58.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.